New antiretroviral drugs

Clinical Microbiology and Infection

Volumn 9, Issue 3, 2003, Pages 186-193

  Gulick, Roy M ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Antiretroviral drugs; Entry inhibitors; HIV therapy; Integrase inhibitors; Protease inhibitors; Reverse transcriptase inhibitors

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ABACAVIR; AMDOXOVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR; DARUNAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; INTEGRASE INHIBITOR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; T 1249; TENOFOVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FAILURE; MEMBRANE FUSION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; VIRUS RESISTANCE; VIRUS STRAIN;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0037367636     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2003.00570.x     Document Type: Review

References (62)

1. Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents February 4, 2002: http://www.hivatis.org.
2. Yeni PG, Hammer SM, Carpenter CCJ et al. Antiretroviral treatment for adult HIV infection in 2002 - updated recommendations of the International AIDS Society - USA Panel. JAMA 2000; 283: 381-90.
3. BHIVA Writing Committee on behalf of the BHIVA Executive Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2: 276-313.
4. Delfraissy J-F. New French guidelines for antiretroviral treatment. HIV Med 2000; 1: 133-6.
5. Mouton Y, Alfandari S, Valette M et al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centers. AIDS 1997; 11: F101-F105.
6. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infections. N Engl J Med 1998; 338: 853-60.
7. Gatell JM. From amprenavir to GW433908 (review). J HIV Ther 2001; 6: 95-9.
8. Lee W, He G, Mulato A et al. In vivo and in vitro characterization of GS 7340, an isopropylalaninyl phenyl ester prodrug of tenofovir; selective intracellular activation of GS 7340 leads to preferential distribution in lymphatic tissues. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 384-T.
9. Gish RG, Leung NWY, Wright TL et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother 2002; 46: 1734-40.
10. Schinazi RF, McMillian A, Cannon D et al. Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl) -1,3-oxathiolan-5-yl]-cytosine. Antimicrob Agents Chemother 1992; 36: 2423-31.
11. Feng JY, Shi J, Schinazi RF, Anderson KS. Mechanistic studies show that (-) -FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP. FASEB J 1999; 13: 1511-7.
12. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993; 90: 5653-6.
13. Lascoux-Combes C, Peytavin G, Perusat S et al. Pharmacokinetics (PK) of a once-daily combination with emtricitabine, didanosine and efavirenz in treatment naive HIV-infected adults (ANRS 091 Trial). In: Abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens, 2001: abstract P222.
14. Molina J-M, Ferchal F, Rancinan C et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000; 182: 599-602.
15. Molina JM, Ferchal F, Journot V et al. Once-daily combination therapy with emtricitabine, didanosine and efavirenz in treatment naive HIV-infected adults 96 week follow-up of the ANRS 091 trial. In: Abstracts of the 8th European Conference on Clinical Aspects and Treatment of HIV Infection. Athens: 2001; abstract P221.
16. Van der Horst C, Benson C, Rodriguez A, Hulett L, Wakeford C, Quinn J. Long-term efficacy and safety of emtricitabine (FTC) in HIV+ adults switching from a lamivudine (3TC) containing HAART regimen. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001; abstract I-1932.
17. Zeier M, Sanne I, Van der Berg M, Quinn J, Shaw A. Efficacy and safety of emtricitabine (FTC) triple combination therapy in HIV-1 infected treatment-naive male and female patients. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001: Abstract I-1933.
18. Fuman PA, Jeffrey J, Kiefer LL et al. Mechanism of action of 1-α-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1- α-D-dioxolane guanosine. Antimicrob Agents Chemother 2001; 45: 158-65.
19. Mewshaw JP, Myrick FT, Wakefield DACS et al. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. JAIDS 2002; 29: 11-20.
20. Eron JJ, Kessler H, Thompson M et al. Clinical HIV suppression after short term monotherapy with DAPD. In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto, 2000: abstract 690.
21. Raffi F, Kessler H, Thompson M et al. Anti-HIV activity of DAPD in treatment-naive and treatment-experienced subjects. AIDS 2000; 14: S18(abstract P5).
22. Corbett JW, Ko SS, Rodgers JD et al. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999; 43: 2893-7.
23. Corbett JW, Ko SS, Rodgers JD et al. Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. J Med Chem 2000; 43: 2019-30.
24. Ruiz N, Nusrat R, Lauenroth-Mai E et al. Study DPC 083-203, a phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 6.
25. Ruiz N, Nusrat R, Lazzarin A et al. Study DPC 083-201: A phase II double-blind (DB) comparison of 3 once daily doses of the NNRTI DPC 083 vs. efavirenz (EFV) in combination with 2 NRTIs in HIV antiretroviral (ARV) treatment-naive patients. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 7.
26. De Bethune M, Hertogs K, Azihn H et al. R165335-TMC125, a third generation nonnucleoside reverse transcriptase inhibitor (NNRTI), inhibits 97% of more than 1000 recombinant NNRTI resistant HIV clinical isolates with an IC50 below 100 nM. AIDS 2000; 14: S17(abstract P2).
27. Gruzdev B, Rakhmanova A, De Dier K et al. TMC125 is a highly potent non-nucleoside reverse transcriptase inhibitor (NNRTI) in antiretroviral therapy (ART) -naive, HIV-1 infected subjects. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Chicago, 2001: abstract I-668.
28. Gazzard B, Pozniak A, Arasteh K et al. TMC 125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1- infected individuals with phenotypic NNRTI resistance. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 4.
29. Robinson BS, Riccardi KA, Gong Y-F et al. BMS-232,632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000; 44: 2093-9.
30. Gong Y-F, Robinson BS, Rose RE et al. In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232,632. Antimicrob Agents Chemother 2000; 44: 2319-26.
31. Aldrovandi G, Samson P, Fenton T, Schnittman S, Rutstein R. Genotypic and phenotypic resistance to BMS 232632 (atazanavir - ATV), among heavily experienced pediatric patients who were ATV-naïve. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 811-W.
32. O'Mara EM, Smith J, Olsen SJ, Tanner T, Schuster AE, Kaul S. BMS-232,632: single and multiple oral dose safety and pharmacokinetic study in healthy volunteers. In: Abstracts of the 7th Conference on Retroviruses and Opportunistic Infections. San Francisco, 1999: abstract 604.
33. Sanne I, Cahn P, Percival L et al. Comparative results (phase II 48-week): BMS-232632, stavudine, lamivudine as HAART for treatment-naïve HIV (+) patients (AI424-008). In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001: abstract I-667.
34. Haas D, Zala C, Schrader S, Thiry A, McGovern R, Schnittman S. Atazanavir plus saquinavir once daily favorably affects total cholesterol (TC), fasting triglyceride (TG), and fasting LDL cholesterol (LDL) profiles in patients failing prior therapy (trial AI424-009, week 48). In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 42.
35. Piliero PJ, Cahn P, Pantaleo G et al. Atazanavir: a once-daily protease inhibitor with a superior lipid profile - results of clinical trials beyond week 48. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002; abstract 706-T.
36. Turner SR, Strohbach JW, Tommasi RA et al. Tipranavir (PNU-140690): a potent, orally bioavailable nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998; 41: 3467-76.
37. McCallister S, Sabo J, Galitz L, Mayers D. An open-label steady state investigation of the pharmacokinetics (PK) of tipranavir (TPV) and ritonavir (RTV) and their effects on cytochrome P-450 (3A4) activity in normal healthy volunteers. (BI 1182.5). In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 434-W.
38. Larder BA, Hertogs K, Bloor S et al. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000; 14: 1943-8.
39. Slater L, Farthing C, Jayaweera J et al. Safety and efficacy of tipranavir (TPV), a novel non-peptidic protease inhibitor, plus ritonavir (RTV), in PI-failure patients. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001: abstract LB-5.
40. Schwartz R, Kazanjian P, Slater L et al. Resistance to tipranavir is uncommon in a randomized trial of tipranavir/ritonavir (TPV/RTV) in multiple PI-failure patients (BI 1182.2). In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002; abstract 562-T.
41. Yoshimura K, Kato R, Kavlick MF et al. A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site. J Virol 2002; 76: 1349-58.
42. De Bethune M, Wigerinck P, Jonckheere H et al. TMC 114, a highly potent protease inhibitor (PI) with an excellent profile against HIV variants highly resistant to current PIs. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001: abstract F-, 1677.
43. Van Der Geest R, Van Der Sandt I, Gille D, Groen K, Tritsmans L, Stoffels P. Safety, tolerability and pharmacokinetics of escalating single oral doses of TMC 114, a novel protease inhibitor (PI) highly active against HIV-1 variants resistant to other PIs. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2001; abstract I-1934.
44. Allaway GP, Davis-Bruno KL, Beaudry GA et al. Expression and characterization of CD4-IgG2, a novel hetrotetramer which neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995; 11: 533-9.
45. Franti M, O'Neill T, Maddon P, Burton D, Poignard P, Olson W. PRO 542 (CD4-IgG2) has a profound impact on HIV-1 replication in the Hu-PBL-SCID mouse model. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 401-T.
46. Jacobson JM, Lowy I, Fletcher CV et al. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000; 182: 326-9.
47. Shearer WT, Israel RJ, Starr S et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. J Infect Dis 2000; 182: 1774-9.
48. Strizki JM, Xu S, Wagner NE et al. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-infection in vitro and in vivo. Proc Natl Acad Sci 2001; 98: 12718-23.
49. Moore J. HIV-1 escape from small molecule CCR5 inhibitors in PBMC does not involve co-receptor switching to CXCR4 use. In: Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires, 2002: abstract LB-, 05.
50. Reyes G. Development of CCR5 antagonists as a new class of anti-HIV therapeutic. IN. Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, February 4-8; 2001: abstract L-11.
51. Reynes J, Rouzier R, Kanouni T et al. SCH C. safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 1.
52. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion (letter). AIDS Res Human Retrovirus 1993; 9: 1051-3.
53. Kilby JM, Hopkins S, Venetta TM et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998; 4: 1302-7.
54. Wie X, Decker JM, Liu H et al. Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 2002; 46: 1896-905.
55. Lalezari J, Cohen C, Eron J, Kilby M, Nelson E, Sista P. Forty-eight week analysis of patients receiving T-20 as a component of multi-drug salvage therapy. In: Abstracts of the XIII International AIDS Conference. Durban, 2000: abstract LbPp116.
56. Lalezari J, DeJesus E, Northfelt D et al. A week 48 assessment of a randomized, controlled, open-label phase II trial (T20-206) evaluating 3 doses of T-20 in PI-experienced, NNRTI-naïve patients infected with HIV-1. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002; abstract 418-W.
57. Clotet B, Lazzarin A, Cooper D et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in Europe and Australia. In: Abstracts of the XIV International AIDS Conference. Barcelona, 2002: abstract LbOr19A.
58. Henry K, Lalezari J, O'Hearn M et al. Enfuvirtide (T-20) in combination with an optimized background (OB) regimen vs. OB alone in patients with prior experience or resistance to each of the three classes of approved antiretrovirals (ARVs) in North America and Brazil. In: Abstracts of the XIV International AIDS Conference. Barcelona, 2002: abstract LbOr19B.
59. Eron J, Merigan T, Kilby M et al. A 14-day assessment of the safety, pharmacokinetics, and antiviral activity of T-1249, a peptide inhibitor of membrane fusion. In: Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections. Chicago, 2001: abstract 14.
60. Miralles G, Demasi R, Sista P, Melby T, Duff F, Matthews T. Genotypic resistance to protease and reverse transcriptase inhibitors and antiretroviral history do not affect virologic response to T-1249. In: Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, 2002; abstract I-, 669.
61. Hazuda DJ, Felock P, Witmer M et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-50.
62. Yoshinaga T, Sato A, Fujishita T, Fujiwara T. S-1360: in vitro activity of a new HIV-1 integrase inhibitor in clinical development. In: Abstracts of the 9th Conference on Retroviruses and Opportunistic Infections. Seattle, 2002: abstract 8.